GSK plc's subsidiary, TESARO, has started legal action against AnaptysBio, alleging a breach of their license agreement regarding the drug Jemperli on November 20, 2025, which could lead to a 50% reduction in payments to AnaptysBio. GSK asserts all allegations from AnaptysBio are without merit and claims significant growth for Jemperli in various countries.